Position in PFE
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$5,466
-$470,944 QoQ
Shares Held
227
-98.6% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#2,761
of 2,820 holders
Holding Since
Dec 2023
4 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in PFE Over Time
Shares Held
Position Value (USD)
Derivatives in PFE
reported options exposure · as of Dec 31, 2023CallValue
$17,274,000
CallShares
600,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Quarry LP holds $1,233,687 across 11 Drug Manufacturers - General names. PFE ranks #7 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
1,382 | $350,986 | |
| 2 | GILD |
Gilead Sciences, Inc.
|
2,631 | $332,400 | |
| 3 | BMY |
Bristol Myers Squibb Co
|
5,660 | $326,129 | |
| 4 | OGN |
Organon & Co.
|
9,891 | $133,924 | |
| 5 | LLY |
ELI LILLY & Co
|
40 | $47,977 | |
| 6 | AZN |
Astrazeneca PLC
|
165 | $31,287 | |
| 7 | PFE |
Pfizer Inc
This page
|
227 | $5,466 | |
| 8 | ABBV |
AbbVie Inc.
|
11 | $2,768 |
All Filings in PFE
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $5,466 | 227 | Shares | Other | 2026-08-14 | |
| 2024-09-30 | $476,410 | 16,462 | Shares | Other | 2024-11-14 | |
| 2024-06-30 | $30,750 | 1,099 | Shares | Other | 2024-08-14 | |
| 2023-12-31 | $17,274,000 | 600,000 | Call | Other | 2024-02-20 | |
| No filing history on record for this holder in this stock. | ||||||